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Complex regulation of T cell functions during pregnancy is required to ensure materno-
fetal tolerance. Here we reveal a novel pathway for the temporary suppression of
maternal T cell responses in uncomplicated human pregnancies. Our results show that
arginase activity is significantly increased in the peripheral blood of pregnant women
and remarkably high arginase activities are expressed in term placentae. High
enzymatic activity results in high turnover of its substrate L-arginine and concomitant
reduction of this amino acid in the microenvironment. Amino acid deprivation is
emerging as a regulatory pathway of lymphocyte responses and we assessed the
consequences of this enhanced arginase activity on T cell responses. Arginase-mediated
L-arginine depletion induces down-regulation of CD3f, the main signalling chain of the
TCR, and functional T cell hyporesponsiveness. Importantly, this arginase-mediated
T cell suppression was reversible, as inhibition of arginase activity or addition of
exogenous L-arginine restored CD3f chain expression and T cell proliferation. Thus,
L-arginine metabolism constitutes a novel physiological mechanism contributing to the
temporary suppression of the maternal immune response during human pregnancy.
Introduction
The success of pregnancies poses an unresolved
immunological challenge: the survival of the semi-
allogeneic fetus in utero is critically dependent upon the
induction of unresponsiveness of the maternal immune
system, while the ability to respond to pathogens and
other antigenic challenges needs to be retained. The
mechanisms underlying immune tolerance during
pregnancy are not fully understood. Over 50 years
ago, Medawar [1] proposed three potential mechanisms
that contribute to immunological unresponsiveness of
the mother to the fetus, anatomic separation, antigenic
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immaturity of the fetus, and suppression or modification
of the maternal immune system during pregnancy.
Much progress has been made in the understanding of
the immune mechanisms that prevent rejection of the
fetus; however, this process is still not entirely
elucidated in humans. Some of the salient features of
the complex relationship between the maternal immune
system and the fetus are starting to be understood, and it
is accepted that multiple mechanisms provided by both
the mother and the fetus contribute to the development
and maintenance of tolerance and immune privilege
[2]. T lymphocytes can acquire tolerance in the thymus
and in the periphery. Peripheral tolerance accounts for
the “unresponsiveness” of T cells to tissue that express
unique antigens. The placenta uniquely expresses
allogeneic antigens and there is evidence that control
or tolerization of anti-fetal Tcells is critical [3]. It is clear
that the maternal immune system is aware of fetal
alloantigens during gestation, but is functionally
tolerant of them until shortly after parturition [4].
Thus, transient suppression of the maternal immune
response is necessary for fetal survival, and it is likely
that several interconnected mechanisms have evolved to
prevent rejection of the fetus. Recently, the inhibitory
T cell costimulatory molecule programmed cell death
ligand 1 has been shown to play a critical role in
preventing maternal immune responses against the
fetus and increasing apoptosis of T cells was considered
as a potential mechanism [5]. A role for Fas-FasL, HLA-G
or TRAIL-TRAIL-R in the apoptosis of maternal leuko-
cytes during pregnancy has been shown in humans and
in animal models [6–8]. Furthermore, regulatory T cells
have also been implicated in the maintenance of
tolerance and the prevention of maternal allogeneic
responses against the fetus [9–11]. Indoleamine 2,3
dioxgenase (IDO), a tryptophan-catabolizing enzyme
expressed in macrophages, dendritic cells and extra-
villous trophoblasts has also been identified as one of
the mechanisms that plays a role in induction of
tolerance and maintenance of allogeneic pregnancies
[12–14]. Despite the acceptance that pregnancy is
associated with suppression of cell-mediated immune
responses, the mechanisms regulating this suppression
are not well defined [15]. In the work we present here
we have identified a novel pathway for the temporary
suppression of immune responses in normal pregnan-
cies.
The immunoregulatory function of L-arginine and of
arginase, one of its metabolising enzymes, is increas-
ingly recognized [16–20]. Modulation of Tcell responses
by arginase-induced L-arginine depletion is emerging as
an important immunoregulatory pathway as demon-
strated in vitro [21, 22], in animal models of infection
[23–25], and in tumour evasion in humans [17–19].
L-Arginine is a semi-essential amino acid, i.e., it can be
synthesized by adult humans, butmust be supplemented
by diet at times of physiological or pathological stress,
such as pregnancy and fetal development [26]. It plays
an essential role in protein synthesis and ammonia
detoxification. Arginase, the final enzyme in the urea
cycle, is responsible for the hydrolysis of L-arginine into
urea and ornithine, which are further metabolized to
proline or polyamines [27]. Two arginase isoforms exist
(I and II), and these differ in subcellular localization,
regulation and function [28]. It has been recently shown
that during immune responses, consumption of
L-arginine by arginase reduces the bioavailability of
this amino acid in the microenvironment; this depletion
of L-arginine induces down-regulation of CD3f chain
expression in activated Tcells [20, 29]. Down-regulation
of CD3f expression results in uncoupling of the TCR
signal transduction pathways and functional T cell
hyporesponsiveness [30].
In the present study we investigated the expression
and activity of arginase in human pregnancies, and
determined the functional consequences of placental
arginase onTcell responses. Our data show that arginase
activity is enhanced in normal term pregnancy and that
the activity of this enzyme is one of the mechanisms
contributing to the suppression of maternal immune
responses by reducing the bioavailability of L-arginine
and leading to down-regulation of CD3f expression and
induction of functional T cell hyporesponsiveness.
Results
Enhanced arginase expression in pregnancy
Arginase has been purified from human placenta [31],
but its role has not been characterized. We hypothesized
that placental arginase induces T cell hyporesponsive-
ness, and that this is one of the mechanisms causing
suppression of the maternal immune system in preg-
nancy. To test our hypothesis, we first measured arginase
activity in cells isolated from human placenta (PlaC)
immediately after parturition, and compared it with
arginase activity in maternal peripheral blood mono-
nuclear cells (PBMC) and PBMC from age-matched
female non-pregnant controls. In all cases, arginase
activity in PlaC was significantly higher than in paired
PBMC (Fig. 1a, left panel). Although arginase activity in
PBMC from pregnant women was notably lower than in
PlaC, it was still significantly higher than in PBMC from
controls (Fig.1a, right panel). Determination of arginase
protein by Western blot confirmed that higher arginase I
protein expression was found in PlaC (Fig. 1b); however,
arginase II expression was not detectable (data not
shown). Sera prepared from maternal blood collected at
the time of birth also contained significantly higher
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arginase activities than sera from controls (Fig. 1c),
indicating an increased arginine turnover in vivo.
Identification of the arginase-expressing cell type
The type of arginase-expressing cells in the placenta was
determined by a combination of intracellular protein
staining and cell surface labelling. Arginase-expressing
cells were identified in region A (forward scatter/side
scatter plot, Fig. 2a) and were contained in the CD14–
and CD14low populations (Fig. 2b, regions B and C);
monocytic CD14high cells did not express arginase I
(Fig. 2b, region D). The majority of arginase-expressing
cells were neutrophils (CD15+CD14– and
CD15+CD14low, Fig. 2c, upper left and upper right dot
plots). Another small population of arginase-expressing
cells was identified within the CD14low population.
These were alternatively activated macrophages, as
characterized by the co-expression of the mannose
receptor CD206 (Fig. 2c, lower left dot plot). Thus, two
populations of cells express arginase in suspensions
obtained from placental biopsies: neutrophils and
alternatively activated macrophages.
Neutrophils are the main arginase-expressing cells in
the placental biopsies; however, it is not known whether
arginase activity in neutrophils isolated from peripheral
blood of pregnant women is higher than in non-
pregnant controls. To answer this question, we isolated
neutrophils from blood obtained at the time of delivery
and compared it to neutrophils isolated from the
peripheral blood of non-pregnant controls. The results
in Fig. 2d clearly demonstrate that arginase activity was
significantly higher in peripheral blood neutrophils from
pregnant women. Similar results were obtained by flow
cytometry by comparing the mean fluorescence inten-
sities (MFI) of arginase I expression in peripheral blood
neutrophils from pregnant women with those from non-
pregnant controls (2.1  0.3 vs.1.3  0.1, respectively).
The MFI of arginase I expression of neutrophils isolated
from paired placental biopsies and peripheral blood of
the same pregnant women were similar (1.9  0.4 vs.
2.1  0.3, respectively).
Figure 1. Arginase is enhanced in pregnancy. (a) PlaC (n=9)
and maternal PBMC (n=9) were isolated and arginase activity
was measured in cell lysates (left panel). Arginase activities
in maternal PBMC were compared to those found in PBMC
from age-matched non-pregnant controls (right panel). Each
symbol represents arginase activity of the cells from one
individual and the horizontal bar represents the median.
Statistical differences were determined using the Mann-
Whitney test: left panel *p<0.0001, right panel *p=0.008. (b)
Arginase protein expression was measured in cell lysates
(30 lg/sample) from paired individuals and from controls by
Western blot as previously described [24, 53]. hAI: recombi-
nant human arginase I. (c) Arginase activity wasmeasured in
maternal (n=9; open circles) and non-pregnant control sera
(n=9; open squares). Each symbol represents the urea content
in the serum of one individual and the horizontal bar
represents the median. Statistical differences were deter-
mined using the Mann-Whitney test: *p=0.006.
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Figure 2. Identification of arginase expressing cells. (a) Identification of arginase I-expressing cells. The region containing cells
expressing arginase I (A)was identified by back-gating ungated arginase I-positive cells (U) on the side scatter/forward scatter plot.
(b) Frequency of arginase I-expressing cells. In region A, two populations of CD14+ cells were identified: CD14low (C) and CD14high
(D)(CD14–: B, dotted line: unstained cells). The frequency of arginase-expressing cells was determined in region B (CD14–), C
(CD14low) and D (CD14high). The markers of histograms and dot-plot were set according to the fluorescence of unstained cells and
the value in parenthesis represents the percentage of cells positive for the isotype control. Data show the results of one
representative experiment out of four independent experiments. (c) Neutrophils and alternatively activatedmacrophages express
arginase I. Arginase I was expressed in 77.8% of CD15+CD14– cells (upper left), 90.8% of CD15+CD14low cells (upper right) and 25.3%
of CD14lowCD206+ cells (lower left); the isotype control for arginase I in CD14lowCD206+ is shown in the lower right (1.7%).Data show
the results of one representative experiment out of four independent experiments. (d) Arginase activity in peripheral neutrophils
is increased during pregnancy. Neutrophilswere isolated by double-density gradient centrifugation of HistopaqueJ-1119 and 1077
and arginase activitywasmeasured as described inMaterial andmethods. Each symbol represents arginase activity of the cells from
one individual and the horizontal bar represents the median. Statistical differences were determined using the Mann-Whitney
test: *p=0.02.
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Determination of the functional consequences of
placental arginase activity
To examine the functional effect of placental arginase,
PlaC and Jurkat cells were co-cultured to assay arginase-
induced modulation of T cell responsiveness [21, 29].
Co-culture of PlaC with Jurkat cells resulted in both
down-regulation of CD3f chain expression (Fig. 3a) and
decreased proliferation of Jurkat cells (Fig. 3b). Im-
portantly, CD3f chain expression and Tcell proliferation
could be restored by addition of either a competitive
arginase inhibitor, Nx-hydroxy-nor-L-arginine (nor-
NOHA [32]) or by the addition of exogenous L-arginine
(Fig. 3a, b). In contrast, maternal PBMC had no effect on
CD3f chain expression or proliferation of Jurkat cells.
These results demonstrate that PlaC can mediate CD3f
chain down-regulation and T cell hyporesponsiveness
through arginase-mediated L-arginine depletion.
CD3f down-regulation in TCR+ cells from
placental biopsies is reversible by modulating
L-arginine metabolism
To determine the functional consequences of local
arginase activity on T cells within the placenta, we
examined the expression of CD3f in TCR+ cells in
placental cell suspensions directly ex vivo. In all
individuals examined, CD3f chain expression was
significantly reduced in TCR+ cells derived from
placental biopsies as compared to maternal T lympho-
cytes in peripheral blood (average reduction:
40.8  2.8%) (Fig. 4a, b). These results demonstrate
that CD3f chain expression is down-regulated in TCR+
cells in the placenta, a compartment with high arginase
activity. Since TCR+ cells circulate between placenta and
periphery, we speculated that this down-regulation
would be reversible, to allow the maternal immune
system to respond to other antigenic challenges whilst
maintaining a state of non-responsiveness against the
fetus. To test this, we assessed whether CD3f down-
regulation in TCR+ cells from placental tissues could be
reversed. In the presence of L-arginine, TCR-mediated
stimulation of PlaC resulted in increased CD3f chain
expression in TCR+ cells; in the absence of exogenous
L-arginine no recovery was observed (Fig. 4c, left
panel). This shows that CD3f chain down-regulation in
TCR+ cells in placental tissues is reversible. A functional
correlate of CD3f chain expression is the ability of cells
to proliferate. TCR+ cells obtained from placental tissues
and stimulated in the presence of L-arginine retain this
ability (Fig. 4c, right panel). These experiments
demonstrate that the functional phenotype of TCR+
cells from placental biopsies is reversible and that the
reduced responsiveness of these T cells cannot be due to
apoptosis.
Figure 3. PlaC have the capacity to down-regulate CD3f chain and suppress proliferation of Jurkat cells in an arginase-/L-arginine-
dependentmanner. PlaC ormaternal PBMC (2  105 cells) were incubatedwith 1  105 Jurkat cells in a final volumeof 200 lL in the
presence or in the absence of 10 lL 5.6 lM nor-NOHA or 2 lL 100 mM L-arginine. After 2 days, MFI of CD3f in TCR+ cells (a) or
frequency of TCR+ cells incorporating BrdU (b) were determined. Jurkat cells were identified by increased side /forward scatter. A
100% response represents the value of the MFI of CD3f (a: MFI =4.6) or the percentage of proliferating Jurkat cells (b: 36.3%) in the
cultures containing Jurkat cells alone. Data show the average  SEM of three independent experiments.
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Figure 4. Down-regulation of CD3f chain in T cells from placental biopsies. (a) MFI of CD3f chain expression was determined in
maternal TCR+ PBMC (dotted line) and in TCR+ PlaC (solid line). The data show the result of 1 representative experiment out of 13
independent experiments. (b) Each symbol represents the MFI of CD3f in peripheral TCR+ cells (closed circles) and paired TCR+
cells from placental biopsies (open circles) from one individual (left panel, n=13). Percent reduction in CD3fMFI in TCR+ cells from
PlaC as compared to TCR+ cells frommaternal PBMC (right panel). (c) Down-regulation of CD3f chain andproliferation of TCR+ PlaC
is reversible. PlaC (4  105) were stimulatedwith plate-bound anti-CD3 and anti-CD28mAb in a final volume of 200 lL in complete
DMEM in the absence of L-arginine, or in complete DMEM containing 0.1, 0.4, 1 or 2 mM L-arginine. At the indicated times post
stimulation, cells were harvested and the MFI of CD3f in TCR+ cells (left panel) or the frequency of TCR+ cells incorporating BrdU
(right panel) were determined. Similar resultswere obtainedwith all the concentrations of L-arginine tested and the data show the
results obtained with 1 mM. Data show the results of one representative experiment out of four independent experiments.
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Impact of placental arginase on autologous
peripheral T cells
Finally, to confirm the role of placental arginase and
L-arginine in mediating T cell hyporesponsiveness,
autologous maternal PBMC were stimulated in the
presence of PlaC, and the effects of arginase inhibition or
addition of exogenous L-arginine on maternal TCR+
cells were assessed. Competitive inhibition of arginase
(nor-NOHA) resulted in a clear up-regulation of CD3f
chain in maternal TCR+ cells (Fig. 5a); similarly,
addition of exogenous L-arginine also enhanced CD3f
expression (Fig. 5b). In agreement with these data, the
proliferative response of maternal TCR+ cells was also
increased in the presence of nor-NOHA or exogenous
L-arginine (Fig. 5c). These results demonstrate that PlaC
can mediate local and reversible T cell hyporesponsive-
ness in the placenta, directly linking arginase and the
bioavailability of L-arginine to feto-maternal tolerance.
Discussion
The survival of the semi-allogeneic fetus is critically
dependent upon the induction of unresponsiveness of
the maternal immune system. Here we reveal a
physiological mechanism whereby arginase can mediate
suppression of maternal T cell responses. We show that
high arginase activity is present in cells isolated from
placenta, and that the source of arginase is mainly
neutrophils and a population of alternatively activated
macrophages. It has to be noted that arginase levels in
cells obtained from placental biopsies are comparable to
those in the liver, the organ with the highest arginase
concentration in the human body [28]. High arginase
levels in the placenta imply a high rate of substrate
consumption and decreased levels of extracellular
L-arginine. This is supported by down-regulation of
CD3f chain expression in TCR+ PlaC, a finding
consistently associated with L-arginine depletion [20,
21, 29]. Although T cell hyporesponsiveness associated
with down-regulated CD3f chain has been observed in a
variety of disease manifestation, the molecular mechan-
isms leading to the down-regulation of one of the main
the signalling chains of the TCR and the associated
Figure 5. Down-regulation of CD3f chain and proliferation by
PlaC is restored by inhibition of arginase or by addition of L-
arginine. PlaC (2  105) were stimulatedwith plate-bound anti-
CD3mAb and anti-CD28mAb in a final volume of 100 ll DMEM
(0.1 mM L-arginine). Then 10 lL nor-NOHA (5.6 lM) was added
to some of thewells, and 30 min later maternal PBMC (1  105,
labeled with CFSE to differentiate maternal TCR+ from
placental TCR+) were added in a final volume of 100 lL. L-
Arginine (2 lL 100 mM) was added to some of the wells. (a, b)
After 2 days, the cells were harvested and the expression of
CD3fwas determined inmaternal TCR+ cells (CFSE+ cells). Data
show the results of one representative experiment out of three
independent experiments. (c) The frequency of cells having
undergone at least one cell division was determined in
maternal TCR+ CFSE+ cells. Data show the results  SD of
one representative experiment out of three independent
experiments.
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immune suppression are not well defined. We show here
that the T cell hyporesponsiveness in human pregnancy
is reversible and that T cells in the placenta retain their
capacity to respond to stimulation. In addition, PlaC co-
cultured with peripheral blood lymphocytes induce
arginase-dependent, L-arginine mediated T cell hypo-
responsiveness, indicating a novel pathway through
which immune privilege can be mediated at the feto-
maternal interface.
In accordance with our finding that the majority of
arginase-expressing cells in the cell population obtained
from placental biopsies are neutrophils, some authors of
the current study have recently identified human
granulocytes, the largest subpopulation of myeloid
cells, as the main subset of arginase I-expressing cell.
They demonstrated that arginase I, which is localized in
azurophil granules of these cells is a novel fungicidal
effector pathway [33]. Moreover, arginase from gran-
ulocytes of patients with purulent inflammation has
immunosuppressive effector functions; it induces pro-
found suppression of T cell proliferation and cytokine
synthesis via arginase-mediated arginine depletion [34].
The anti-inflammatory function of arginase-expressing
human neutrophils supports the concept that neutro-
phils can not only initiate but also contribute to the
resolution of inflammation. Neutrophils are one of the
key cell types contributing to innate and adaptive
immune responses and it is known that changes in their
functional properties occur during pregnancy [33, 35,
36]. The placenta is a likely site of immunoregulation
and indeed, trophoblasts have been shown to regulate
the activation status of neutrophils [37]. Proinflamma-
tory responses and placental oxidative damage have
been associated with pregnancy complications such as
preeclampsia, miscarriage and preterm labor [38, 39].
Thus, human granulocyte arginase constitutes a novel
homeostatic immunoregulatory mechanism that limits
inadequate or excessive immune activation.
L-Arginine metabolism is emerging as an important
regulator of T cell responses in humans [20]. Arginase-
expressing polymorphonuclear granulocytes in renal
cell carcinoma patients have been shown to impair Tcell
responses through depletion of L-arginine in the
extracellular environment [17], and inhibition of
arginase has been shown to boost anti-tumour T cell
responses, and reverses the anergic state of tumour-
infiltrating T lymphocytes in human prostate cancers
[18]. In patients with active pulmonary tuberculosis, a
correlation between T cell hyporesponsiveness and
arginase-mediated L-arginine depletion has also been
described [40]. Interestingly, and in accordance with the
findings we report here, the T cell hyporesponsiveness
was reversible: T cells of patients that responded to anti-
tuberculosis therapy re-expressed the signal transducing
proteins [40]. L-Arginine has been shown to play a role
in the regulation of mRNA translation [41, 42], and,
while the exact mechanism through which it mediates
T cell unresponsiveness is unclear, it is likely that
reduced protein synthesis contributes to this effect.
Immunoregulation via arginase-mediated L-arginine
depletion has similarities with the well-characterized
effects of IDO-mediated tryptophan degradation. IDO
exerts its antimicrobial effector functions via the
depletion of amino acid essential for microbial growth
[43] and it suppresses immune responses. The trypto-
phan metabolism plays an analogous role in regulation
of maternal immune responses in the mouse and
pioneering work has revealed that placental cells
expressing IDO induce the catabolism of tryptophan,
which results in suppression of maternal Tcell activation
and prevents rejection of allogeneic fetuses [12]. In the
mouse, limiting tryptophan availability appears to be an
important mechanism by which the local microenviron-
ment can influence the outcome of Tcell activation [13].
Interestingly, in contrast to the striking effects of
chemical inhibition of IDO in allogeneic pregnancies,
genetic elimination of IDO did not affect fetal viability
and pregnancy success rates. These studies indicate that
alternative compensatory or redundant mechanisms
prevent fetal rejection [44]. We have identified another
physiological pathway, the arginase inducedmetabolism
of L-arginine that results in T cell hyporesponsiveness in
normal human pregnancies. Similarly to the reported
discrepancies in the IDO model, inhibition of arginase
activity in vivo using chemical inhibitors affects the
reproductive process in a rat model [45]. A later study
confirmed the anti-fertility effects of blocking arginase
activity and showed that it acts mainly by inhibiting
implantation or by increasing resorption of implants
[46]. Inactivation of the arginase gene, however, did not
affect pregnancy success since heterozygous arginase
I-knockout mice produced the statistically expected rate
of homozygous arginase-deficient offspring [47], which
died within 2 weeks after birth of hyperammonemia. It
is likely that both IDO and arginase reduce the
bioavailability of amino acids and exert their immuno-
modulatory function using similar pathways to silence
T cells. An important distinction between immune
hyporesponsiveness mediated by IDO and that induced
by arginase is that the former results in apoptosis of
Tcells [48], whereas the hyporesponsiveness induced by
placental arginase is reversible. Immunoregulation by
amino acid availability has also been reported for
cysteine. Cysteine depletion leads to cell cycle arrest in
human T cells due to intracellular glutathione reduction
and altered redox regulation [49].
Our results strengthen the evidence for the immu-
noregulatory potential of amino acid metabolism.
Arginase-mediated T cell hyporesponsiveness is not only
relevant for the understanding of suppression of
Pascale Kropf et al. Eur. J. Immunol. 2007. 37: 935–945942
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
maternal immune responses during pregnancy, it has
wider implications and will contribute to the under-
standing of peripheral tolerance or unresponsiveness in
a wide range of infectious diseases and pathologies.
Modulation of T cell responses by these metabolic
pathways will open new avenues of therapeutic
intervention for a wide range of pathological conditions.
Materials and methods
Subjects
The study protocol was approved by the local Ethics
Committee of St. Mary's NHS Trust, London (COREC
reference 05/Q0403). Twenty-six pregnant women (mean
age 31.0  6.0 years) were recruited at the time of uncom-
plicated spontaneous vaginal delivery or elective caesarian
section. Exclusion criteria included any major complication of
pregnancy or intercurrent illness, such as pre-eclampsia, pre-
or post-term labor (<38 weeks or >42 weeks), intra-uterine
growth retardation, gestational diabetes, or viral or parasitic
infections. Nomajor differences were observed in cells isolated
from placentae obtained from spontaneous vaginal delivery or
by caesarian section.
Twenty-one healthy, non-pregnant women (mean age
29.6  6.1 years) were recruited as controls. All subjects gave
written, informed consent before participation.
Samples
Blood was collected in EDTA tubes, PBMC were isolated by
density gradient centrifugation on HistopaqueJ-1077 and
neutrophils by double density gradient centrifugation on
HistopaqueJ-1119 and HistopaqueJ-1077. Cells were washed
and resuspended in PBS until further use.
Whole placentae were harvested directly after parturition
and biopsies were taken through the full thickness of the
placenta. Single cell suspensions were obtained by homo-
genising biopsies in PBS on cell dissociation sieves; a
Histopaque gradient was performed to eliminate debris and
the cells obtained from these placental biopsies (PlaC) were
washed and resuspended in PBS until further use. Granulo-
cytes (<3%) are virtually excluded from purified PBMC from
healthy donors; their sedimentation with PlaC is likely to be
due to in vivo activation since it has been shown that receptor-
mediated granulocyte activation leads to changes in their
density [50].
Arginase activity
The enzymatic activity of arginase was measured as previously
described [24, 33, 51]. Briefly, cells were lysed with 100 lL of
0.1% Triton X-100. After 30 min on a shaker, 100 lL 25 mM
Tris-HCl was added. To 100 lL of this lysate, 10 lL 10 mM
MnCl2 was added, and the enzymewas activated by heating for
10 min at 56C. Arginine hydrolysis was conducted by
incubating the lysate with 100 lL 0.5 M L-arginine (pH 9.7)
at 37C for 15–20 min. The reaction was stopped with 800 lL
H2SO4 (96%)/H3PO4 (85%)/H2O (1:3:7, v/v/v). The urea
concentration was measured at 540 nm after addition of 40 lL
a-isonitrosopropiophenone (dissolved in 100% ethanol) fol-
lowed by heating at 95C for 30 min. To determine arginase
activity in the sera, urea concentrations were first determined
in the sera, without the activation and hydrolysis steps; these
values were subtracted from those obtained by measuring the
urea levels as described above.
One unit of enzyme activity is defined as the amount of
enzyme that catalyzes the formation of 1 lmol of urea per min.
Western blot analysis
Arginase I and II protein expression were measured as
described previously [33, 52, 53]. Equal amounts of protein
(30 lg/condition) from PBMC and PlaC were resolved by SDS-
12% gel electrophoresis and transferred to polyvinylidene
difluoride (PVDF) membranes. Briefly, proteins were trans-
ferred (250 mA for 60 min) to PVDF membranes using a Mini
Trans-Blot Cell apparatus (Bio-Rad). The procedure for
immunodetection includes transfer, blocking of the membrane
(30 min at 37C) with 10 mM Tris-HCl pH 7.5, 150 mM NaCl
and 0.2% Tween-20 (TTBS) containing 10% non-fat dried milk
and incubating (60 min at room temperature) with the
primary antibody (anti-arginase I rabbit polyclonal antibody
[24] and anti-arginase II rabbit polyclonal IgG, Santa Cruz
Biotechnology, were used to detect arginase). After washing
(two times for 5 min with TTBS), membranes were incubated
(60 min at room temperature) with peroxidase-conjugated
secondary antibodies (1:5000 in TTBS with 10% non-fat dried
milk). After washing (two times for 5 min and once for
10 min), detection of bound antibodies was visualized by
chemiluminescence using the ECLTM-plus reagent (Amer-
sham). Semi-quantification of was performed by enhanced
chemiluminescence. The signal was detected by GelDoc system
(Bio-Radf) and quantified with Quantity-One-1D analysis
software (Bio-Radf). Human arginase I was a generous gift
from Dr. S. D. Cederbaum.
Flow cytometric analysis
Antibodies used were as follows: anti-CD3f (Santa Cruz: clone
6B10.2), anti-CD14 (BD Pharmingen: cloneM5E2, Beckman
Coulter: RMO52), anti-CD206 (BD Pharmingen: clone 19.2),
anti-TCR (BD Pharmingen: clone T10B9.1A-31, eBioscience:
clone IP26), anti-BrdU (with DNase, BD Pharmingen: clone
B44); anti-arginase I (HyCult Biotechnology: clone 6G3) and
the isotype control (BD Pharmingen: clone MOPC21) were
coupled with Alexa FluorR 488 (Molecular Probes). BrdU (BD
Pharmingen) and CFSE (Molecular Probes) were added at a
final concentration of 10 lM and 0.4 mM, respectively. BrdU
was added during the last 4 h of culture. Cells were washed
with PBS, the fixation step was performed with 2%
formaldehyde in PBS and the permeabilisation step with
0.5% saponin in PBS. For the intracellular detection of
arginase I, 1  106 PlaC were incubated with 20 lL FcR
blocking reagent for 20 min at room temperature. Anti-CD14,
anti-CD15 and anti-CD206 mAb were added directly to the
tubes. After 20 min at 4C, the cells were washed, fixed and
permeabilised and resuspended in 200 lL PBS/5% FBS; 20 lL
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FcR blocking reagent was added to the cells for 5 min. Then
0.2 lg FITC-conjugated anti-arginase I or mouse FITC-
conjugated IgG1 was added to the cells, and 20 min later
the cells were washed. The cells were analysed with an EPICS
XL instrument (Beckman Coulter).
Cell culture
PlaC, maternal PBMC and control PBMC were stimulated with
plate-bound anti-CD3mAb (30 ng, Serotec: clone UCHT1) and
anti-CD28 mAb (3 ng, Serotec: clone YTH913.12).
Dulbecco's modified essential medium (DMEM, 0.4 mM
L-arginine unless stated otherwise) and DMEM without
L-arginine (Gibco) were supplemented with 50 IU/mL peni-
cillin, 50 lg/mL Streptomycin, 292 lg/mL L-glutamine and
5% FBS.
Statistical analyses
Data were evaluated using the Mann-Whitney test with
GraphPad PRISM version 2.0.
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